The Ready, Set, PrEP program is designed to provide Gilead Sciences' Truvada and Descovy to up to 200,000 people who do not have prescription drug insurance coverage. Gilead is donating supplies of both drugs.
Although Descovy showed an advantageous side-effect profile, one doctor described Truvada as mostly well-tolerated, while another said switching to Descovy will depend on insurance coverage. Both expressed a desire for data in other vulnerable populations.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.